{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:26Z","timestamp":1786987706077,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"am","delay-in-days":254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20mk0101159"],"award-info":[{"award-number":["JP20mk0101159"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.dmpk.2021.100396","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T19:06:34Z","timestamp":1618340794000},"page":"100396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-468X","authenticated-orcid":false,"given":"Yukihiro","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tamemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-1374","authenticated-orcid":false,"given":"Sheelendra Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Yoshitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Hozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2021.100396_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-019-00750-8","article-title":"Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016","volume":"58","author":"Saravanakumar","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2021.100396_bib4","author":"Ministry of Labor and Welfare"},{"key":"10.1016\/j.dmpk.2021.100396_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cbi.2004.09.015","article-title":"In\u00a0vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol","volume":"150","author":"Usmani","year":"2004","journal-title":"Chem-Biol Interact"},{"key":"10.1016\/j.dmpk.2021.100396_bib6","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.tiv.2012.05.003","article-title":"The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches","volume":"27","author":"Abass","year":"2013","journal-title":"Toxicol In\u00a0Vitro"},{"key":"10.1016\/j.dmpk.2021.100396_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpba.2014.03.018","article-title":"A\u00a0cocktail approach for assessing the in\u00a0vitro activity of human cytochrome P450s: an overview of current methodologies","volume":"101","author":"Spaggiari","year":"2014","journal-title":"J\u00a0Pharmaceut Biomed Anal"},{"key":"10.1016\/j.dmpk.2021.100396_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dmpk.2021.100396_bib9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos: The Biological Fate of Chemicals"},{"key":"10.1016\/j.dmpk.2021.100396_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5980\/jpnjurol1989.83.518","article-title":"In-vivo enhancement of neutrophil function by administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in cyclophosphamide (CPA) treated mice","volume":"83","author":"Yoshida","year":"1992","journal-title":"Jpn J Urol"},{"key":"10.1016\/j.dmpk.2021.100396_bib11","first-page":"719","article-title":"Chemotherapy-induced alopecia in mice -Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone","volume":"144","author":"Paus","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.dmpk.2021.100396_bib12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jcph.878","article-title":"Cytochrome p450 genetic variations can predict mRNA expression, cyclophosphamide 4-hydroxylation, and treatment outcomes in Chinese patients with non-Hodgkin\u2019s lymphoma","volume":"57","author":"Shu","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2021.100396_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A\u00a0comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.dmpk.2021.100396_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.taap.2016.04.013","article-title":"An extensive cocktail approach for rapid risk assessment of in\u00a0vitro CYP450 direct reversible inhibition by xenobiotic exposure","volume":"302","author":"Spaggiari","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmpk.2021.100396_bib18","article-title":"Kinetics of cyclophosphamide metabolism in human, dog, cat, and mouse and relationship to cytotoxic activity and pharmacokinetics","volume":"47","author":"Ramirez","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2021.100396_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.dmpk.2021.100396_bib20","doi-asserted-by":"crossref","first-page":"16205","DOI":"10.1021\/bi961950t","article-title":"Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP2C9","volume":"35","author":"Mancy","year":"1996","journal-title":"Biochemist"},{"key":"10.1016\/j.dmpk.2021.100396_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1248\/yakushi.125.795","article-title":"Drug-drug interaction of antifungal drugs","volume":"125","author":"Niwa","year":"2005","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.dmpk.2021.100396_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1254\/fpj.128.93","article-title":"Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor","volume":"128","author":"Niwa","year":"2006","journal-title":"Folia Pharmacol Jpn"},{"key":"10.1016\/j.dmpk.2021.100396_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in\u00a0vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2021.100396_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/aps.2016.10","article-title":"An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s","volume":"37","author":"Chen","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmpk.2021.100396_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"Saari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2021.100396_bib26","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In\u00a0vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2021.100396_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","article-title":"A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug\u2013drug interactions","volume":"59","author":"Li","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2021.100396_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2021.100396_bib29","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3389\/fimmu.2019.03130","article-title":"Mouse models and tools for the in\u00a0vivo study of neutrophils","volume":"10","author":"Stackowicz","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.dmpk.2021.100396_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270007309703","article-title":"Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects","volume":"48","author":"Liu","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2021.100396_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J\u00a0Pharmacol Exp Therapeut"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:55:40Z","timestamp":1761162940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436721000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"alternative-id":["S1347436721000173"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100396","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100396"}}